Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy

被引：0
|
作者：
Shohei Takaichi
Yoshito Tomimaru
Shogo Kobayashi
Keisuke Toya
Kazuki Sasaki
Yoshifumi Iwagami
Daisaku Yamada
Takehiro Noda
Hidenori Takahashi
Tadafumi Asaoka
Masahiro Tanemura
Yuichiro Doki
Hidetoshi Eguchi
机构：
[1] Osaka University Graduate School of Medicine,Department of Gastroenterological Surgery
[2] Osaka Police Hospital,Department of Surgery
[3] Rinku General Medical Center,Department of Surgery
来源：
Annals of Surgical Oncology | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2458 / 2468
页数：10
相关论文
共 50 条
  • [41] Neoadjuvant Chemoradiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
    Shafi, S.
    Kaubisch, A.
    PANCREAS, 2015, 44 (08) : 1413 - 1413
  • [42] Efficacy of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma
    Kang, J.
    Kim, K-P.
    Yoo, C.
    Lee, J-L.
    Ryoo, B-Y.
    Chang, H-M.
    Lee, S. S.
    Park, D. H.
    Song, T. J.
    Seo, D. W.
    Lee, S. K.
    Kim, M-H.
    Hwang, D. W.
    Song, K. B.
    Lee, J. H.
    Kim, S. C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [43] Neoadjuvant Therapy for Achieving Margin Negative Resection in Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Chandrasekaran, S.
    Coveler, A. L.
    Chandrasekaran, S.
    Lucas, F. R.
    Patel, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S314 - S314
  • [44] Factors associated with Failure to Reach Surgical Resection in Patients undergoing Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma
    Gleisner, A. L.
    Miller, J. L.
    Assifi, M.
    Steve, J. Y.
    Bartlett, D. L.
    Hogg, M. E.
    Zeh, H. J.
    Zureikat, A. H.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S177 - S177
  • [45] Neoadjuvant Chemotherapy and Radiation Improves Recurrence-free and Overall Survival in Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Kelley, Jesse K.
    Kolbeinsson, Hordur
    Chandana, Sreenivasa
    Eastburg, Benjamin
    Frisch, Austin
    Parker, Jessica
    Wright, G. Paul
    Assifi, M. Mura
    Chung, Mathew
    AMERICAN SURGEON, 2024,
  • [46] Local Immunological Effect of Neoadjuvant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Cancer
    Murakami, T.
    Mori, R.
    Matsuyama, R.
    Homma, Y.
    Nakazawa, M.
    Tanaka, Y.
    Miyake, K.
    Sawada, Y.
    Oota, Y.
    Hiroshima, Y.
    Kumamoto, T.
    Ueda, M.
    Takeda, K.
    Ichikawa, Y.
    Tanaka, K.
    Endo, I.
    PANCREAS, 2014, 43 (08) : 1394 - 1394
  • [47] Residual total pancreatectomy of borderline resectable pancreatic adenocarcinoma after neoadjuvant chemotherapy: A case report
    Hata, Shojiro
    Shimizu, Atushi
    Yamaguchi, Kazuhiro
    Teruya, Masanori
    Kaminishi, Michio
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 262 - 262
  • [48] Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer
    Cho, In Rae
    Chung, Moon Jae
    Bang, Seungmin
    Park, Seung Woo
    Chung, Jae Bock
    Song, Si Young
    Seong, Jinsil
    Hwang, Ho Kyoung
    Kang, Chang Moo
    Lee, Woo Jung
    Park, Jeong Youp
    PANCREATOLOGY, 2013, 13 (05) : 539 - 543
  • [49] Neoadjuvant chemoradiotherapy with S-1 in patients with borderline resectable pancreatic cancer
    Hattori, Masashi
    Fujii, Tsutomu
    Suenaga, Masaya
    Yamada, Suguru
    Kanda, Mitsuro
    Iwata, Naoki
    Kobayashi, Daisuke
    Tanaka, Chie
    Nakayama, Goro
    Sugimoto, Hiroyuki
    Koike, Masahiko
    Nomoto, Shuji
    Fujiwara, Michitaka
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [50] Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
    Trinh, Katherine, V
    Fischer, Dawn A.
    Gardner, Timothy B.
    Smith, Kerrington D.
    FRONTIERS IN ONCOLOGY, 2020, 10
12345